Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

18F-Fluselenamyl

Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER